IP Library Granted Patent US 7,427,402
Granted Patent B2
US 7,427,402 · App. 11/635,960 · Granted Sep 23, 2008

Method of evaluating inflammatory skin disorders using IL-17 and/or IL-19

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,427,402
App. No.
11/635,960
Granted
Sep 23, 2008
Kind
B2
Abstract

Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.

Claims (17)

1. A method of evaluating the propensity of a subject to develop an inflammatory skin disorder comprising:

a) obtaining a non-lesional skin sample from the subject;

b) quantifying the level of IL-17A, IL-17F or IL-19 expression in the skin sample; and

c) comparing the level of IL-17A, IL-17F or IL-19 in the skin sample to the level in normal skin samples, wherein higher levels of expression of IL-17A, IL-17F or IL-19 than normal skin indicate a propensity of the subject to develop an inflammatory skin disorder.

2. The method of claim 1 , wherein the IL-17A, IL-17F or IL-19 expression is mRNA expression.

3. The method of claim 1 , wherein the level of IL-17A, IL-17F or IL-19 expression is quantified by real-time PCR.

4. The method of claim 1 , wherein the inflammatory skin disorder is cutaneous inflammation.

5. The method of claim 4 , wherein the cutaneous inflammation is psoriasis.

6. The method of claim 1 , wherein the level of IL-17A or IL-17F expression in the skin sample is at least 5-fold higher than normal skin.

7. The method of claim 1 , wherein the level of IL-19 expression in the skin sample is at least 20-fold higher than normal skin.

8. The method of claim 1 , wherein the subject has:

a) a family history of psoriasis; or

b) previously presented psoriatic symptoms.

9. The method of claim 1 , wherein the subject is a human.

10. The method of claim 1 , wherein the level of IL-17A or IL-17F expression in the skin sample is 2 to 50 fold higher than normal skin.

11. The method of claim 10 , wherein the level of IL-17A or IL-17F expression in the skin sample is 5 to 20 fold higher than normal skin.

12. The method of claim 1 , wherein the level of IL-19 expression in the skin sample is 5 to 130 fold higher than normal skin.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →